|
Report Date : |
24.05.2014 |
|
|
|
|
Tel. No.: |
18-75-662-8967 / 81-75-662-8973 |
IDENTIFICATION DETAILS
|
Name : |
ARKRAY GLOBAL BUSINESS INC |
|
|
|
|
Registered Office : |
Kyoto Miyuki Bldg 10F, 689 Karasumadori Shijo-Noboru Nakagyoku Kyoto 604-8153 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.10.2008 (Estimated Consolidated Financials – parent Company Arkray Inc.) |
|
|
|
|
Date of Incorporation : |
July
2001 |
|
|
|
|
Com. Reg. No.: |
1300-01-023753 (Kyoto-Nakagyoku) |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Exporter of diabetes-related clinical equipment & supplies,
reagents, functional foods as overseas trading division of Arkray Inc to over
80 countries worldwide |
|
|
|
|
No of Employees : |
25 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
Japan ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a
comparatively small defense allocation (1% of GDP) helped Japan develop a
technologically advanced economy. Two notable characteristics of the post-war
economy were the close interlocking structures of manufacturers, suppliers, and
distributors, known as keiretsu, and the guarantee of lifetime employment for a
substantial portion of the urban labor force. Both features are now eroding under
the dual pressures of global competition and domestic demographic change.
Japan's industrial sector is heavily dependent on imported raw materials and
fuels. A small agricultural sector is highly subsidized and protected, with
crop yields among the highest in the world. While self-sufficient in rice
production, Japan imports about 60% of its food on a caloric basis. For three
decades, overall real economic growth had been spectacular - a 10% average in
the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth
slowed markedly in the 1990s, averaging just 1.7%, largely because of the after
effects of inefficient investment and an asset price bubble in the late 1980s
that required a protracted period of time for firms to reduce excess debt,
capital, and labor. Modest economic growth continued after 2000, but the
economy has fallen into recession three times since 2008. A sharp downturn in
business investment and global demand for Japan's exports in late 2008 pushed
Japan into recession. Government stimulus spending helped the economy recover
in late 2009 and 2010, but the economy contracted again in 2011 as the massive
9.0 magnitude earthquake and the ensuing tsunami in March disrupted
manufacturing. The economy has largely recovered in the two years since the
disaster, but reconstruction in the Tohoku region has been uneven. Prime
Minister Shinzo ABE has declared the economy his government's top priority; he
has overturned his predecessor's plan to permanently close nuclear power plants
and is pursuing an economic revitalization agenda of fiscal stimulus, monetary
easing, and structural reform. Japan joined the Trans Pacific Partnership
negotiations in 2013, a pact that would open Japan's economy to increased
foreign competition and create new export opportunities for Japanese
businesses. Measured on a purchasing power parity (PPP) basis that adjusts for
price differences, Japan in 2013 stood as the fourth-largest economy in the
world after second-place China, which surpassed Japan in 2001, and third-place
India, which edged out Japan in 2012. The new government will continue a
longstanding debate on restructuring the economy and reining in Japan's huge
government debt, which is exceeding 230% of GDP. To help raise government
revenue and reduce public debt, Japan decided in 2013 to gradually increase the
consumption tax to a total of 10% by the year 2015. Japan is making progress on
ending deflation due to a weaker yen and higher energy costs, but reliance on
exports to drive growth and an aging, shrinking population pose other major
long-term challenges for the economy.
|
Source : CIA |
ARKRAY GLOBAL BUSINESS INC
Arkray Global
Business KK (Overseas trading division of Arkray Inc)
Kyoto Miyuki Bldg 10F, 689 Karasumadori Shijo-Noboru Nakagyoku Kyoto
604-8153 JAPAN
Tel:
075-662-8967 Fax: 075-662-8973
*.. The given address is its Group Laboratory at: 57 Nishi-Aketacho
Higashi Kujo Minamiku Kyoto 601-8045, as given
URL: www.arkray.co.jp
E-Mail address: (thru the URL)
Exporter of diabetes-related clinical
equipment & supplies, reagents, functional foods as overseas trading
division of Arkray Inc to over 80 countries worldwide
Group
branches nationwide (Tot 25)
Europe,
Australia, USA, China, Korea, India, Philippines (--Group Subsidiary & sales offices)
Shiga
(2); (Overseas): China, USA (--Group mfrs)
YOSUKE
NAKANISHI, PRES
Yen
Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen Not disclosed M
PAYMENTS Unknown
CAPITAL Yen 20 M
TREND UNDETD WORTH Yen
Not disclosed M
STARTED 2001 EMPLOYES 25
OVERSEAS BUSINESS & TRADING OPERATIONS OF ARKRAY INC GROUP.
.
FINANCIAL SITUATION CONSIDERED
FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject company was established on the basis of an overseas trading
division separated from Arkray Inc, mfg of diabetes-related clinical instruments,
at the caption address. This is an
overseas trading division of the parent with management and staff members fully
integrated with the parent, Arkray Inc.
Specializes in exporting the goods of the parent to over 80 countries
worldwide. Sales offices are in Europe,
USA, Australia, China, Korea, India, Philippines, other.
(Group firms):
Domestic: Arkray Marketing
Inc (Domestic marketing division);
Arkray Global Business Inc (International marketing division); Arkray
Infinity Inc, Arkray Factory Inc (--Mfg divisions); Karada Lab Inc (Functional
foods)
Overseas: China (5),
Korea, Singapore, Indonesia, Philippines (2), India, Netherlands, UK, Poland,
USA (4)
Financials are consolidated by the parent, Arkray Inc, and not individually
disclosed. The parent, however,
disclosed them until Oct/2007 fiscal term and not ever since.
The sales volume of the parent for Oct/2007 fiscal term amounted to Yen
37,420 million, a 33% down from Yen 54,300 million in the previous term. The net profit was posted at Yen 782 million,
compared with Yen 160 million a year ago.
The net worth was Yen 30,904 million.
The financial situation is considered FAIR and good for ORDINARY
business engagements.
Date Registered: Jul 2001
Regd No.: 1300-01-023753 (Kyoto-Nakagyoku)
Legal Status:
Limited Company (Kabushiki Kaisha)
Authorized:
1,600 shares
Issued: 400
shares
Sum: Yen 20
million
Major shareholders (%):
Arkray Inc*(100)
*.. Mfr of diabetes-related clinical testing equipment, at the caption
address, founded 1963, capital Yen 99 million, sales Yen 37,420 million, net
profit Yen 782 million, employees 1,613 (group employees), pres Takeshi
Matsuda;
Nothing detrimental is known as to the commercial morality of executives.
Activities: Exports
diabetes-related clinical equipment & supplies, reagents, functional foods
as overseas trading division of Arkray Inc to over 80 countries worldwide
(--100%).
(Handling items):
Automatic Glico-hemoglobin Analyzer, Fully Automated Urine Analyzer,
Versatile Urine Analysis System, Compact Urine Analyzer, Urine test strips, Dry
Clinical Chemistry Analyzer, Automated analyzer for clinical chemistry,
Electrolyte Analyzer with Ion-Selective Electrodes, Blood Ammonia Meter, Blood
glucose test meter, Lancet device for blood collection, Osmotic Pressure,
Simplified Blood Lactate Test Meter,
(Principal
overseas clients):
Bayer Corporation (USA); A Menarini Diagnostic (Italy); Tamro
Corporation (Finland);
Axon Lab AG (Switz); Heska Corporation (USA); IRIS (USA), Bayer Corp, A
Menarini, Tamro Corp, other
Clients: [Hospitals,
laboratories, medical institutions] Exports to USA, Germany, Italy, Korea,
China, India, Philippines, UK, other.
No. of accounts: Unavailable
Domestic areas of activities: Nationwide
Suppliers: [Mfr] Supplied
wholly from the parent, Arkray Inc & group firms.
Payment record: Unknown
Location: Business area in
Kyoto. Office premises at the caption
address are owned and maintained satisfactorily.
Bank
References:
Bank of Kyoto (Inari)
MUFG (Kyoto-Chuo)
Relations: Satisfactory
(In Million Yen)
NOT DISCLOSED
& UNAVAILABLE
Consolidated
Financials of the parent, Arkray Inc.
|
|
|
31/10/2008 |
31/10/2007 |
31/10/2006 |
31/10/2005 |
|
Annual Sales |
|
38,000 |
37,420 |
55,530 |
5,400 |
|
Recur. Profit |
|
|
1,663 |
|
|
|
Net Profit |
|
800 |
782 |
260 |
222 |
|
Total Assets |
|
|
N/A |
N/A |
N/A |
|
Net Worth |
|
|
36,800 |
36,018 |
35,758 |
|
Capital,
Paid-Up |
|
|
99 |
99 |
99 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
1.55 |
-32.61 |
928.33 |
-89.43 |
|
|
Current Ratio |
.. |
.. |
.. |
||
|
N.Worth Ratio |
.. |
.. |
.. |
||
|
N.Profit/Sales |
2.11 |
2.09 |
0.47 |
4.11 |
|
Note:
Financials are only partially disclosed.
No financials are disclosed after Oct.2008 fiscal Term
Forecast
(or estimated) for the 31/10/2008 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.58.48 |
|
UK Pound |
1 |
Rs.98.67 |
|
Euro |
1 |
Rs.79.81 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.